Rebamipide and its Application in Clinical Practice (Literature Review, MetaAnalysis and Personal Experience), Part II. Eradication of Helicobacter Pylori and Rebamipide

Read full text Summarise with VIRAT
Authors: Starostin Boris D
Cited by: 0
References: 67

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Introduction: eradication of Helicobacter pylori (HP) is of great importance in faster scarring of ulcers, preventing recurrence of peptic ulcer disease and its complications, including bleeding, histological regression of acute and chronic gastritis, reducing the severity of atrophy of the gastric mucosa or its elimination with timely treatment, reducing the area of intestinal metaplasia, preventing the development of cancer, possible regression of MALT lymphoma in the early stages, positive effect in unexplained iron deficiency anemia, thrombocytopenic purpura and B12 deficiency anemia, to eliminate rosacea, acne and halitosis. In numerous publications in recent years, there has been a decrease in the effectiveness of anti-Helicobacter therapy (anti-H.p.). A decrease in the effectiveness of anti-H.p. therapy led to a search for methods to optimize such therapy, one of which is the addition of the mucoprotective drug rebamipide. The Aim: of our work was to evaluate the impact of the effectiveness of adding rebampide to various anti-H.p. dual therapy, triple therapy and quadruple therapy. Methods: each topic of the drug’s use was evaluated from the point of view of evidence-based medicine. 16 studies were included for evaluation: 6 with dual therapy, 8 with triple therapy (the study of Vyalov S.S., 2017 was excluded from the analysis due to the fact that it was presented as an abstract and rebamipide was administered at a dose of 100 mg 2 times a day – off lable), and 2 with quadruple therapy. Results: of the 6 studies dual PPIs-based anti-H.p. therapy, 4 showed no significant differences in H.p. eradication, with p>0.05, while 2 showed significant differences, with p

Fields of Study & Subjects

Helicobacter pylori-related gastroenterology studies Gastrointestinal motility and disorders Hepatitis C virus research

Publication details

Pages
1–15
Publication date
26 March 2026
Language
EN